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Abstract 
Recreational MDMA use is a worldwide problem. Tablet dosage varies, thus entailing a 
requirement for quantitative analysis. The quantification of MDMA in tablets using benchtop 
1H NMR spectroscopy via either linear regression (‘manual’ method) or partial least square 
regression (‘automated’ method) approaches are reported, without the need for an internal 
standard, and compared against contemporaneously obtained GC-MS data. Twenty samples 
were evaluated of which 15 were proven to contain MDMA, via qualitative NMR (hit score 
≥0.97) and GC-MS (Rt = 5.6 min) analysis. Quantitative NMR analysis showed that the mean 
value of MDMA content was 42.6% w/w by the manual method and 45.9% w/w by the 
automated method. The mean value obtained from GC analysis was 44.0% w/w. A substantial 
proportion (n = 9) of the tablets tested possessed >190 mg of MDMA (range 133-223 mg, 
average of all techniques’ calculations for each tablet). This value is higher than the reported 
average MDMA content of tablets by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), which was ca. 125 mg of MDMA per tablet in 2016. 
 
Highlights 
 Quantitative analysis of MDMA is achieved using a benchtop NMR spectrometer 
 NMR-based quantification using linear or partial least square regression is described 
and the values obtained compared against contemporaneously obtained GC-MS data 
 NMR-based quantification is achieved without an internal standard 
 
1. Introduction 
3,4-Methylenedioxymethamphetamine (MDMA, 1, Fig. 1) is a synthetic entactogen, which 
shares a structural similarity to methamphetamine (2) and acts upon the central nervous system 
(CNS) producing mood enhancement, increased energy and other empathetic effects by 
increasing the intra-synaptic concentrations of the key neurotransmitters serotonin, dopamine 
and norephinephrine [1-5].  MDMA was first synthesised by Merck in 1912 as a potential 
appetite suppressant. Over the next century, the psychedelic properties of MDMA were 
explored[6], culminating in recent clinical trials demonstrating initial safety and efficacy for 
its treatment of post-traumatic stress disorder (PTSD), with potential for expansion to 




Fig. 1.  Structures of 3,4-methylenedioxymethamphetamine (MDMA, 1), methamphetamine 
(2) and 2,5-dimethoxy-4-bromophenethylamine (2C-B, 3) hydrochloride. 
During the 1970s and 80s, MDMA surfaced on the recreational drugs market. The widespread 
abuse and potential long-term health effects of MDMA led many countries to prohibit its 
possession, supply and manufacture. Currently in the UK, MDMA (or “ecstasy”) is controlled 
as a Class A, Schedule 1 substance due to its illicit use as a recreational drug and its implication 
in a number of highly publicized fatalities [8-14].  The psychoactive substance is extremely 
prevalent [15-17] and encountered normally in tablet form, with each batch stamped with a 
particular motif e.g. the “Mitsubishi”, “Punisher” or “Superman” logos, smiley faces or 
lettering. A number of UK-based studies have looked at the MDMA content within these 
formulations [18-21].  The first UK study by Cole et al., carried out in 2002, employed high 
performance liquid chromatography (HPLC) to analyse a number of “White Dove” tablets (n 
= 82) obtained from the North West of England (1991 – 2001) and determined that MDMA 
content within these samples ranged from 73 – 89 mg with a mean content of 78.8 mg [21].  
Subsequently Wood et al. also used HPLC to quantify the amount of MDMA present within 
surrendered ecstasy pills (n = 101) obtained from nightclubs in both London and Swansea in 
2006.  The researchers reported that the mean level (58.7 mg) in the samples was significantly 
lower than seen by Cole et al., with a MDMA content ranging from 20 – 131 mg per tablet 
[19].  In 2019, liquid chromatography-tandem mass spectrometry (LC-MS-MS) was used by 
Couchman et al. to quantify the MDMA content within tablets (n = 412) collected from venues 
across the UK over a seventeen year period (2001 – 2018).  The study demonstrated that the 
median amount of MDMA present was 74 mg with a range of 3 – 255 mg per tablet [18].  More 
recently, Blagbrough et al. have disclosed the ultra-high performance liquid chromatography 
(UHPLC) and high field nuclear magnetic resonance (NMR) analysis of ecstasy pills (n = 26) 
and the mean content within these products was 119.7 mg MDMA (range: 72.9 – 166.5 mg per 
tablet) [20]. Though there have been a number of reports of “super pills” (270 – 340 mg) 
circulating in the UK market, these quantitative studies support that the UK trend is in line with 
data reported by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
which indicated an average MDMA content of tablets in 2016 as being ca. 125 mg [22].  
 
Recreational MDMA/ecstasy use is a worldwide problem, due to its frequent use within 
nightclubs and music festivals.  Recently, it was reported that MDMA was the most prevalent 
drug (40%) in a qualitative study that analysed 432 samples [15]. Cocaine (20%) and ketamine 
(17%) were the next most common. Another report from a UK festival onsite drug checking 
service reported that the most common drug identified was MDMA (57%) in either crystal / 
powder form or as pills of 230 tested samples [17]. 13.5% and 10% of samples were ketamine 
and cocaine respectively. Similarly, a report detailing the UK’s first community-based drug 
safety testing in two city centres identified MDMA again as being the most prevalent drug 
(43.3%) out of the 171 samples surveyed [16]. Cocaine and ketamine were the next prevalent; 
each substance accounted for 12.9% of the substances sampled. 
 
A number of groups have reported the quantification of MDMA using HPLC with ultra-violet 
(UV) detection [19, 21, 23-25], quadrupole electrospray time-of-flight (ESI-QTOF) UHPLC 
[20], gas chromatography-flame ionisation detection (GC-FID) [26], gas chromatography mass 
spectrometry (GC-MS) [27, 28], LC-MS (or LC-MS-MS) [18, 29-31] and electrochemical 
detection [23].  Chromatographic methods are considered the gold standard in academic and 
commercial forensic laboratories for the quantitative analysis of MDMA, but they suffer from 
some disadvantages (e.g. cost, technical complexity and portability) [32] and are not suitable 
for rapid and routine on-site testing.  Nuclear magnetic resonance (NMR) spectroscopy, despite 
being a powerful analytical technique, has been underutilized for the detection and 
quantification of drugs within samples.  The reason for low uptake of the technique in forensic 
settings is the perceived complexity of the measurement and the inherent cost of a 
superconducting magnet and the associated technical costs. However, a small number of 
studies that focus on the use of NMR spectroscopy to achieve high sample throughput coupled 
with quantification have been reported [20, 26, 33].  Hays disclosed a rapid, reproducible and 
versatile high field 1H NMR method (pulse: 90°; scans: 8; pulse delay: 45 s) for determining 
both the purity and molecular weight of the illicit drugs (including MDMA) and adulterants in 
deuterium oxide using maleic acid (5 mg) as the internal standard [33].  Subsequently de 
Oliveira et al. utilised a 600 MHz 1H NMR instrument to determine the content of MDMA in 
seized tablets (n = 38, 39 – 152 mg per tablet), also using maleic acid as the internal standard 
[26].  The 1H NMR method (pulse: 90°; scans: 16; pulse delay: 25 s) was cross-validated by 
GC-FID and shown to be more efficient and versatile for the detection and quantification of 
the target analyte, in terms of accuracy (< 5% relative error) and precision (<2% relative 
standard deviation) when compared to the GC-FID approach.  More recently, Blagbrough et 
al. have reported the quantification of MDMA in seized tablets (n = 26), and in the presence of 
other psychoactive substances (i.e. methylone, eutylone and 3-trifluoromethylpiperazine), 
using a 1H NMR method (pulse: 90°; scans: 16; pulse delay: 50 s) also acquired on a 600 MHz 
instrument and using maleic acid as the internal standard [20]. 
 
In this paper, the quantification of MDMA using 60 MHz benchtop 1H NMR spectroscopy is 
reported using two different approaches. Benchtop NMR was utilised for this study due to the 
low running costs and ease of operation [34], which might be attractive to legal entities and 
healthcare providers interested in the screening of suspected MDMA tablets. The first approach 
employed is based on simple linear regression onto peak integrals, which we will call the 
‘manual’ method. The second approach uses partial least squares regression of the MDMA 
content onto a wider spectral range; we will call this the ‘automated’ approach. Notably, 
quantification is performed in the absence of an internal standard and the results from the 1H 
NMR analysis are compared against contemporaneously obtained GC-MS data. 
 
2. Experimental 
2.1 Instrumentation and materials 
All reagents were of commercial quality (Sigma-Aldrich, Gillingham, UK or Fluorochem 
Limited, Hadfield, UK) and used without further purification. Solvents (Fisher Scientific, 
Loughborough, UK) were dried, where necessary, using standard procedures [35].  Racemic 
3,4-methylenedioxymethamphetamine hydrochloride (MDMA, 1) was prepared in-house 
using an adaptation of the method reported by Buchanan et al. and obtained as colourless 
crystals after recrystallization from isopropanol [36]. High-field 1H NMR (10 mg/600 μL in 
d6-DMSO) and 
13C NMR spectra (20 mg/600 μL in d6-DMSO) were acquired on a JEOL JMN-
ECS-400 (JEOL, Tokyo, Japan) NMR spectrometer operating at a proton resonance frequency 
of 400 MHz and referenced to the residual solvent peak (d6-DMSO: 
1H-NMR δ = 2.50 ppm, 
13C-NMR δ = 39.52 ppm [37] respectively) and filtered prior to analysis. The purity of (1) was 
calculated using the relative concentration NMR determination method described by Pauli et 
al. [38].  Optical rotation values []D
22 (10−1 deg cm2/g) were measured on a Bellingham & 
Stanley ADP-220 polarimeter (Bellingham & Stanley, Tunbridge Wells, UK) (MDMA.HCl, 
[]D
22 = 0 deg cm2/g).  Infrared spectra were obtained in the range 4000 – 400 cm-1 using a 
Thermo Scientific Nicolet iS10ATR-FTIR instrument (Thermo Scientific, Rochester, USA). 
High-resolution mass spectrometry (HRMS) data was obtained on an Agilent 6540 LC-QToF 
spectrometer in positive electrospray ionization mode. Melting points (uncorrected) were 
acquired on a Stuart SMP10 digital melting point apparatus (MDMA.HCl, Mpt. = 208-209°C). 
The twenty suspected MDMA tablets (M1 – M20) were provided to MANchester DRug 
Analysis and Knowledge Exchange (MANDRAKE), between 24th August 2018 – 29th March 
2019, by Greater Manchester Police, in accordance with Manchester Metropolitan University’s 
Home Office license requirements and agreed procedures.  
2.2 Gas chromatography-mass spectrometry (GC-MS) 
GC-MS analysis was performed using an Agilent 7890B GC and a MS5977B mass selective 
detector (Agilent Technologies, Wokingham, UK). The mass spectrometer was operated in the 
electron ionisation mode at 70 eV. Separation was achieved with a capillary column (HP5 MS, 
30 m Å∼ 0.25 mm i.d. 0.25 μm) with helium as the carrier gas at a constant flow rate of 
1.2 mL/min. The oven temperature programme started at 50°C, increased at 30 °C/min and was 
held at 290 °C for 2 minutes. A 2 μL aliquot of the samples (qualitative analysis, calibration 
standards and test solutions) were injected with a split ratio of 50:1. The injector and the GC 
interface temperatures were both maintained at 280°C and 290°C respectively. The MS source 
and quadrupole temperatures were set at 230°C and 150°C, respectively. Mass spectra were 
obtained in full scan mode (50 – 550 amu) [qualitative analysis] and using selective ion 
monitoring mode (SIM) [quantitative analysis], using three specific fragment ions for MDMA 
(tR = 5.6 min , m/z = 135.1, 77.0 and 58.0) and eicosane (tR = 7.2 min, m/z = 71.0, 57.0 and 
43.0) respectively [39].  Calibration standards: 10 mg of MDMA.HCl was weighed accurately 
into a 100.0 mL clear glass class A volumetric flask and diluted to volume with methanol to 
give a solution containing MDMA at 100 μg/mL. This solution was then further diluted with 
methanol and eicosane (100 μg/mL in methanol) added (in each case) to give calibration 
standards containing 5.0 μg/mL, 10.0 μg/mL, 15.0 μg/mL, 20.0 μg/mL and 25.0 μg/mL of each 
analyte and the internal standard at 10.0 μg/mL  The five standards were injected six times.  
Test samples:  In triplicate, 10 mg of the homogenised sample was weighed accurately into a 
100.0 mL clear glass class A volumetric flask and diluted to volume with methanol to give a 
sample solution at 100 μg/mL. This solution was further diluted with methanol and eicosane 
(100 μg/mL in ethanol) added to give a test sample containing 10.0 μg/mL of the sample with 
the internal standard at 10.0 μg/mL. Each seized sample was analysed in this manner twice to 
give two mean % w/w of MDMA present (termed run 1 and run 2).  
2.3 Nuclear magnetic resonance (NMR) spectroscopy 
Low-field 1H NMR spectra were acquired on a bench-top Pulsar® (Oxford Instruments, 
Abingdon, UK) NMR spectrometer operating at a proton resonance frequency of 59.7 MHz.  
The temperature of the probe was calculated to be 308.5 K by measuring the separation (in Hz, 
∆δ) between the CH2 and OH signals of neat ethylene glycol and using the equation T [K] = 
466.5 - 102.00 ∆δ [40].  Qualitative analysis: 5 – 10 mg of the powdered tablet was combined 
with d6-DMSO (600 µL). The solution was filtered using a Whatman
® 0.45 μm PVDF 
(polyvinylidene difluoride) syringe filter (Sigma-Aldrich, Gillingham, UK) directly into an 
NMR tube. After the sample had been inserted into the Pulsar® spectrometer, an automated 
procedure began whereby the instrument would lock on to the deuterated signature of the 
residual solvent peak (d6-DMSO, δ = 2.50 ppm) before acquiring 16 scans.  Following 
acquisition, the data were processed in MNova (Mestrelab Research, Santiago de Compostela, 
Spain) using an automated script file. The processed FID was then analysed using a pattern 
recognition algorithm, developed in-house using Matlab (The Mathworks Inc, Cambridge, 
UK). The algorithm employs a minimum distance classifier. The multivariate distance between 
the sample spectrum and each of the reference spectra is calculated. The sample is identified 
as the nearest reference compound, provided the ‘match score’ (equal to one minus the 
distance) exceeds an (empirically determined) threshold; if it does not, then the outcome is 
considered to be tentative, unreliable or unknown [15].  Quantitative analysis: 50 mg of the 
powdered tablet was combined with d6-DMSO (1 mL). The solution was filtered using a 
Whatman® 0.45 μm PVDF (polyvinylidene difluoride) syringe filter (Sigma-Aldrich, 
Gillingham, UK) directly into an NMR tube.  The individual 1H NMR spectra of the test 
samples were acquired using four scans and a pulse delay of 30 s. The spectra were processed 
using a 1 Hz exponential in the t1 direction and phased accordingly. Integrals of the aromatic 
(H2’, H5’ and H6’), 3,4-methylenedioxy (H5) and methyl (H3) groups were then obtained 
which had been referenced against an MDMA standard (100 mg/mL in d6-DMSO). Each test 
sample was analysed five times. Spectral acquisition of each MDMA sample took ca. 2.5 mins. 
 
3. Results and Discussion 
The synthesis of a reference standard of racemic 3,4-methylenedioxymethamphetamine 
hydrochloride (1) was achieved using a modification of the previously reported method (Route 
2) by Buchanan et al. from piperonylmethyl ketone (PMK) in 68% overall yield after 
recrystallization from isopropanol [36].  The hydrochloride salt was determined to be soluble 
(10 mg mL-1) in methanol and dimethylsulfoxide and its purity confirmed to be >99.5% (by 
NMR).  To ensure the authenticity of the material used in this study, the synthesised sample 
was fully structurally characterised and the spectral data (1H NMR, 13C NMR, FT-IR and GC-
MS) with assignments for the synthesized reference material provided in the Supplementary 
Information (Fig. S1 – S4) for comparison.  Analysis of the low field 1H NMR spectrum (Fig. 
2) of the reference standard highlighted three resonances that could be readily integrated, and 
thus would be easily quantifiable. These were the aromatic C-H signal (three coincident signals, 
H2’, H5’ and H6’), the 3,4-methylenedioxy protons (H5) and the methyl protons (H3) of the 
di-substituted propyl chain at 6.89-6.72, 6.01 and 1.11 ppm respectively. These three signals 
were the focus of subsequent analysis. 
 
Fig. 2. 1H NMR spectrum (60 MHz) of 3,4-methylenedioxymethamphetamine (1, 300 mg/600 
µL in d6-DMSO). The three signals of interest have been highlighted (A = aromatic protons 
[H2’, H5’ and H6’], B = 3,4-methylenedioxy protons [H5], C = methyl protons [H3]) 
 
3.1 Development of the quantitative methodology (‘manual NMR method’) 
In order to quantitate the amount of MDMA present in a sample, the sample must fully relax 
between scans to ensure that representative integrals are obtained. Thus, to develop the 
quantification methodology, a series of samples of MDMA in d6-DMSO in the range 5-
300 mg mL-1 were prepared and these were analysed by 1H NMR spectroscopy to obtain T1 
values for the three resonances of interest. The MDMA range was selected to encompass the 
range reported by the Drug Information and Monitoring Service (DIMS) as being regularly 
encountered (10 mg to >140 mg) [41] and also included so called “super pills” which contain 
≥270 mg of MDMA per tablet [22]. 
 
The T1s for the three signals ranged from 1.8 to 0.4 s over the concentration range investigated. 
The aromatic nuclei had the longest T1 followed by the methylene protons and, finally, the 
methyl protons. A plot of inverse T1 against concentration of MDMA is shown in Figure 3. As 
a sample relaxes in 5-6 T1, the maximum relaxation delay needed to be ca. 12 seconds. 
However, to ensure complete relaxation, a relaxation delay of 30 s was used for quantification 
experiments, therefore facilitating accurate integration of the three peaks identified. Procedures 
published by Blagbrough et al. [20], Hays et al. [33] and de Oliveira et al. [26] utilised 
relaxation times of 50, 45 and 25 s respectively to quantify MDMA by 1H NMR spectroscopy.  
 
Fig. 3. Graph showing the inverse T1 value for the aromatic (H2’, H5’ and H6’, triangles), 3,4-
methylenedioxy (H5, squares) and methyl (H3, circles) protons of MDMA at varying 
concentrations in d6-DMSO 
 
Each of the prepared MDMA samples was then analysed and the three signals of interest 
integrated using the same integral range for each spectrum to ensure consistency. Figure 4 
shows the straight-line plot that was obtained for the average normalised signals of the samples 
utilised. Individual plots for the aromatic (H2’, H5’ and H6’), methylenedioxy (H5) and the 
methyl (H3) signals are included in the SI. The linearity of the plot was expected due to the 
signal intensity being proportional to the amount of 1H nuclei in the sample. 
 
Fig. 4. Averaged normalised signal intensities for different concentrations of MDMA. The 
samples were normalised to the signal intensities for the 50 mg mL-1 samples. The 1H NMR 
spectrum of each sample was collected five times and the average of the normalised signal 
intensity for each acquisition plotted as an individual point on the graph. 
 
The limit of detection (LOD) was calculated for the three calibration plots produced using the 
standard deviation of y-intercepts of the regression line according to the International Council 
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) 
guidelines [42]. The LODs ranged from 5.5 mg mL-1 for the aromatic nuclei (H2’, H5’ and 
H6’) to 6.6 mg mL-1 for the methylenedioxy (H5) nuclei. Similarly, the limit of quantification 
(LOQ) was calculated and values ranged from 16.5 mg mL-1 for the aromatic nuclei to 21.9 mg 
mL-1 for the methylenedioxy nuclei. Table 1 summarises the findings. Using MDMA standards 
from 5 mg mL-1 to 150 mg mL-1 only reduced the LOD and LOQ to mean values of 3.3 and 
10.1 mg mL-1 respectively. Furthermore, the mean signal-to-noise ratio of the three signal areas 
of interest is 36 for the 5 mg mL-1 reference sample. The ICH also states that signal-to-noise 
ratios can be used to determine LOD and LOQ, with typical values being 3:1 and 10:1 
respectively. Employing this approach would imply that the LOD and LOQ are both <5 mg 
mL-1. Given that tablets typically contain 125 mg MDMA [22], the methodology employed is 
sufficient to quantify the material present. It should be noted that the LOQ values reported for 
MDMA quantification using high-field NMR instrumentation (600 MHz), was 0.67% of the 
molar ratio of MDMA relative to the internal standard (maleic acid), which equates to ca. 0.13 
mg [26]. Again, the authors noted that the values are far below the lowest MDMA.HCl 
concentration determined in real samples. The difference in LOQ values could be due to a 
number of factors, the most pertinent being the difference in field strength (60 MHz compared 
to 600 MHz) and the number of scans used, both of which have a direct relationship on the 
signal-to-noise ratio.  
 




(H2’, H5’ and H6’) 
3,4-Methylenedioxy 
protons (H5) 
Methyl protons (H3) 
Slope 0.0165 0.0155 0.0155 
Intercept 0.1486 0.1963 0.1760 
Standard error of the 
intercept 
0.0273 0.0340 0.0310 
LOD / mg mL-1 5.5 7.2 6.6 
LOQ / mg mL-1 16.5 21.9 19.9 
 
3.2 Quantification of MDMA in a simulated mixture 
To test the quantification method, a simulated mixture consisting of 780 mg MDMA 
hydrochloride and 2010 mg CaCO3 was prepared and homogenised. CaCO3 is a frequently 
used pharmaceutical excipient [43]. Aliquots (465 mg) of this powder were analysed using 1H 
NMR spectroscopy. The 1H NMR spectrum obtained was integrated and normalised relative to 
a reference sample of MDMA (50 mg mL-1). Five separate samples were analysed. The mean 
values for the aromatic (H2’, H5’ and H6’) signal, methylene (H5) signal and methyl (H3) 
signal were 133.0±1.8 mg, 123.3±2.2 mg and 132.2±2.1 mg respectively. Using all these 
integrated signals gave an overall mean of 129.5±2.0 mg. Each aliquot should contain 130 mg, 
so the values determined experimentally compare well with the expected value. The approach 
highlights the importance of using more than one signal in order to determine the amount of 
MDMA present in the sample; the lower average value of the methylene signal demonstrates 
this. 
 
3.3 Automating the quantitative analysis (‘automated NMR method’) 
In contrast to the ‘manual’ method, which treats each of the peaks of interest separately, the 
‘automated’ method uses the spectral regions A, B and C as indicated in Fig. 2 simultaneously, 
in a multivariate approach.  Internally cross-validated partial least squares regression (PLSR) 
was applied to these regions of the MDMA calibration series spectra. A 5-factor model was 
found optimal, with an estimated error in prediction of 4.5 mg mL-1. This model was 
subsequently applied to the spectra of the seized samples to obtain predicted MDMA 
concentrations, discussed below. 
 
 
Fig. 5: A: Standard deviation of prediction residuals as a function of PLS model dimensions; 
and B: Cross-validated 5-factor PLS model of MDMA concentrations (actual against predicted) 
 
3.4 Qualitative analysis of the seized tablets 
20 tablets (MD1-MD20) were seized by Greater Manchester Police and provided to 
Manchester Metropolitan University through the MANchester DRug Analysis and Knowledge 
Exchange (MANDRAKE) partnership. All the tablets were suspected to contain MDMA. The 
drugs ranged in appearance as described in table 2. The seized tablets all possessed similar 
weights, with the exception of the green embossed “Twitter” tablets (n = 5). These had a mean 
weight of 0.20±0.03 g; for the remaining tablets (n = 15) the mean weight was 0.44±0.026 g.  
Initial analysis of the tablets was performed using qualitative NMR and GC-MS approaches to 
identify the active pharmaceutical ingredient (API) in each tablet.  
 
The qualitative NMR data was acquired on a benchtop NMR spectrometer (60 MHz). 
Acquisition, analysis, processing and elucidation of the API present in the sample was 
automated, which has been described in full elsewhere.[15] Briefly, an algorithm compares the 
spectral data to a reference library of over 300 1H NMR spectra, ranking matches by a Pearson’s 
correlation-based score. A threshold was set empirically at 0.838: match scores greater than 
this are indicative of a correct match, whereas identifications with lower scores are considered 
unreliable. This approach confirmed that tablets MD1-MD8 and MD14-MD20 all contained 
MDMA as the sole API, as the hit-scores were consistently 0.97 or above. Notably, grouping 
of the hit-scores values, as well as appearance, indicated the presence of six distinct types of 
tablet (four groups of tablets and two single tablets). MD19 and MD20 were the two single 
tablets, which were blue “Punisher” (hit score = 0.970) and blue “Superman” tablets (hit score 
= 0.989) respectively. MD1-MD8 were all red and white “iPhone” tablets, and these all yielded 
a hit-score of 0.986±0.001. MD14-MD16 and MD17-MD18 were pink “Heineken” and beige 
pharaoh tablets respectively, and these two groups had hit scores of 0.989±0 and 0.987±0. The 
final group, five green “Twitter” tablets, MD9-MD13, were identified by the pattern matching 
algorithm as containing the hallucinogenic phenethylamine, 2,5-dimethoxy-4-
bromophenethylamine (2C-B, 3), as the main API. These tablets were not investigated further, 
as the focus of the present study is the development of an automated quantitative NMR method 
for determining the MDMA content of a suspect tablet. Having ascertained that MD1-MD8 
and MD14-MD20 all contained MDMA, the next step was the quantification of this API. 
 
3.5 Quantification of MDMA in seized samples 
The quantification of the seized samples was achieved using the manual and automated NMR 
methods. As both approaches are NMR-based, GC-MS data was also contemporaneously 
collected for comparison purposes. For the manual NMR approach, a reference sample 
consisting of 100 mg of MDMA was acquired, and the spectra of the samples were normalised 
to the reference spectrum in order for the calibration plot to be utilised.   
 
MD1-MD8 all had the same physical appearance (red and white “iPhone” logo) and from the 
GC analysis, all of these tablets were determined to be ca. 50% w/w MDMA (range 209-219 
mg) (Table 2). The amounts of MDMA in the tablets were in the range 200-241 mg as 
determined by the manual NMR method, and 212-244 mg by automated NMR. In general, the 
values from the NMR methods were in good agreement with those from the GC-MS analysis, 
although a few samples gave somewhat higher values for the MDMA present in the tablet. 
Notably, this occurred for MD1, MD2 and MD6. For example, analysis of MD6 produced 
values for the MDMA content that were ca. 5% higher by the NMR methods (240.67±1.2 mg 
by manual, 244.03 mg by automated) than that obtained from the GC-MS analysis (218.86±5.0 
mg). This sample showed the biggest difference between the NMR and GC-MS results. We 
note here a recent study that quantified MDMA in a tablet using UHPLC and NMR using an 
internal standard indicated differences between methods of ca. 8 mg for some of the tablets 
surveyed (ca. 1-1.5% differences in MDMA content w/w) [20]. From consideration of the 
various analyses of MD1-MD8, it is likely that these tablets were all produced from the same 
batch process. Furthermore, the crushed weight of these tablets were very similar; the average 
weight was 0.424±0.008 g.  
 
Analysis of MD14-MD16, the pink “Heineken” tablets, again showed very good agreement 
between the NMR analyses, both automated and manual, and the GC-MS analysis. Similar to 
MD1-MD8, it is likely that MD14-MD16 were all produced from the same batch process. This 
is reflected in near identical qualitative hit scores, similar tablet weights (0.438±0.010 g) and 
similar MDMA contents (36-39% w/w by the NMR methods). GC-MS analysis indicated that 
the tablets contained 171-176 mg of MDMA, whereas the range determined by manual NMR 
was 159-163 mg, and by automated NMR, 165-173 mg.  
 
MD17 and MD18 were two beige pharaoh tablets. These two samples were found to have the 
lowest % w/w MDMA from analysis by GC-MS (ca. 29% w/w). Interestingly, the manual 
NMR method resulted in substantial differences in the amount of MDMA present (5 and 9% 
w/w, equating to 26 and 48 mg difference of MDMA in the tablet compared to GC-MS 
analysis). Conversely, the automated approach gave very good agreement with the GC-MS 
analysis (ca. 29% w/w, 7 or 10 mg difference between automated and GC-MS analysis), 
especially when the estimated error of 4.5 mg mL-1 is accounted for.  
 
The amount of MDMA in MD19 as determined by NMR and GC-MS differed substantially. 
Upon inspection of the 1H NMR spectrum, an additional signal was observed as a downfield 
shoulder (centred at 1.23 ppm) on the methyl (H3) peak. Consequently, the integration value 
obtained for this signal is the combination of the methyl signal of MDMA and the additional 
signal, which is attributed to binder / filler material that was not removed by the filtration 
process performed. Thus, the reported amount of MDMA in the sample is greater than is 
actually the case. The integral values for the aromatic and methylene signals indicate that the 
amount of MDMA present is 24.5±0.5 mg and 23.4±0.5 mg respectively, which equates to 
45.98±1.9% of MDMA in the original 52 mg tablet. This compares well with the GC-MS data 
that reports 44-46% w/w. In contrast, the methyl (H3) signal returns that the sample contains 
28.9±0.3 mg, equivalent to ca. 57% w/w MDMA content in the original tablet. The automated 
NMR outcome is similarly adversely affected; this is due to the multivariate approach treating 
the three spectral regions simultaneously rather than individually. This contrasts to the manual 
approach that treats each spectral region separately prior to reporting the mean of these regions. 
Evidently, the presence of this additional signal complicates the quantitation of MDMA in the 
sample by both the manual or automated approaches, and hence additional scrutiny of the data 
was required. 
 
The additional signal in the 1H NMR spectrum of MD19 is believed to be due to stearate being 
present in the sample. Previously, samples that have been prepared and analysed in the same 
way as described herein were shown to possess this signal [15]. Confirmation was obtained by 
doping a sample with magnesium stearate, which led to a peak at the same chemical shift. Thus, 
care should be taken when quantifying, as additional signals present in the integral regions 
adversely affect the calculation of the amount of MDMA present. The results for MD19 
exemplify that a single integral region should not be used for quantitation by NMR. Notably, 
the qualitative GC-MS analysis returned MDMA only as being present in the sample. It did not 
detect the presence of stearate in the sample as it would need to be derivatized, such as through 
the use of silylating agents [44], in order to be detected.  
 
Finally, analysis of MD20 by the automated NMR method indicated that the tablet contained 
38.6% w/w MMDA (159 mg in the tablet). This compares well with the GC-MS analysis, 
which reported that the tablet contained 157 mg MDMA. However, the manual NMR analysis 
of MD20 was similar to MD17 and MD18, in that the value compared to GC-MS was 5% 
lower. The results for these three samples (MD17, MD18 and MD20) highlight the importance 
of a combined approach in terms of quantifying the amount of MDMA per tablet; a singular 
methodology should not be relied upon.  
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Run 1 Run 2 
MD1 Red and 
white 
iPhone 
0.4417 218.61±2.2 49.56±1.0 49.43±0.8 0.984 0.0500 222.35±1.8 50.34±0.8 241.65 54.71 
MD2 Red and 
white 
iPhone 
0.4331 217.55±2.4 50.29±1.1 50.18±2.8 0.986 0.0495 219.51±1.3 49.54±0.6 236.53 53.58 
MD3 Red and 
white 
iPhone 
0.4261 212.96±1.0 49.92±0.5 50.04±1.8 0.985 0.0539 214.57±1.4 50.36±0.6 217.61 51.07 
MD4 Red and 
white 
iPhone 
0.4189 210.73±0.71 49.81±0.3 50.80±0.6 0.986 0.0522 211.54±1.1 50.50±0.5 221.18 52.8 
MD5 Red and 
white 
iPhone 
0.4202 208.92±2.0 49.94±1.0 49.50±0.7 0.986 0.0479 199.57±0.9 47.49±0.5 212.16 50.49 
MD6 Red and 
white 
iPhone 
0.4329 218.86±5.0 51.43±2.3 49.68±0.8 0.985 0.0493 240.67±1.2 55.59±0.5 244.03 56.37 
MD7 Red and 
white 
iPhone 
0.435 218.42±2.0 50.33±0.9 50.10±0.1 0.987 0.0492 211.75±1.1 48.68±0.5 223.16 51.3 
MD8 Red and 
white 
iPhone 
0.421 208.9±3.8 49.61±1.8 49.63±1.4 0.987 0.0504 209.04±1.2 49.65±0.6 217.36 51.63 
MD14 Pink 
Heineken 
0.45 175.61±4.4 38.68±2.5 39.19±1.6 0.989 0.0511 160.00±1.9 35.56±1.2 173.16 38.48 
MD15 Pink 
Heineken 
0.4334 170.76±2.4 39.82±1.4 38.99±2.1 0.989 0.0506 163.00±5.06 38.89±3.1 171.36 39.86 
MD16 Pink 
Heineken 
0.4299 171.05±2.2 40.21±1.3 39.37±2.6 0.989 0.0519 159.31±3.6 37.06±2.3 165.25 38.44 
MD17 Beige 
pharaoh 
0.4837 137.56±2.4 28.68±1.8 28.20±2.7 0.987 0.0512 111.30±4.6 23.00±4.1 145.50 30.08 
MD18 Beige 
pharaoh 
0.5072 153.45±1.4 30.49±0.9 29.99±0.6 0.987 0.0498 105.04±1.9 20.71±1.8 143.08 28.21 
MD19 Blue 
punisher 
0.4749 214.23±7.6 44.22±3.6 46.00±1.5 0.970 0.0520 233.57±3.9 49.18±1.7 251.74 53.01 
MD20 Blue 
superman 




Twenty seized tablets were analysed, of which 15 were found to contain MDMA via qualitative 
NMR (hit scores ≥0.97) and GC-MS (Rt = 5.6 min) analysis. If MD19 is excluded due to the 
presence of stearate in the analysed sample, which was not removed by the filtration process 
employed, then the qualitative NMR hit score for all samples improves to ≥0.984.  
 
T1 data of MDMA were acquired for samples in the range 5-300 mg mL
-1 to assess the time-
period required for complete relaxation. The aromatic (H2’, H5’ and H6’), 3,4-methylenedioxy 
(H5) and methyl (H3) were selected for analysis due to their isolated nature in the 1H NMR 
spectrum. For the concentrations measured, T1 values ranged from 1.8 to 0.4 s. To ensure 
complete relaxation, a relaxation delay of 30 s was used. For the quantitative analysis by NMR, 
spectral acquisition of each MDMA sample took ca. 2.5 mins to obtain four transients. We can 
conclude that benchtop NMR offers a rapid method for accurate identification of the API. 
Furthermore, due to minimal sample preparation, this approach could be utilised by legal 
entities and healthcare providers for rapid screening of suspected MDMA tablets. 
 
The quantification of MDMA using benchtop 1H NMR spectroscopy was assessed using two 
different approaches. The first was based on simple linear regression onto peak integrals 
(‘manual’ method) whereas the second utilised partial least squares regression of the MDMA 
content onto a wider spectral range (‘automated’). NMR-based quantification was performed 
in the absence of an internal standard to reduce sample preparation. The results from the 1H 
NMR analysis were compared against contemporaneously obtained GC-MS data. The NMR 
quantitative analysis of MD1-MD8 and MD14-MD20 gave mean values for the MDMA 
content across all tablets of 42.6% w/w by the manual method and 45.9% w/w by the automated 
method. The mean value obtained from GC analysis was 44.0% w/w. Notably, this means that 
a substantial proportion of the tablets tested contained >190 mg of MDMA (range 133-223 mg, 
average of all techniques’ calculations for each tablet). A dose of 190 mg MDMA is sufficient 
to produce a physiological effect in a human (>1 mg kg-1 of bodyweight required to induce 
elevated temperature and cardiovascular effects [45], for example).  
 
The MDMA content of the tablets surveyed herein is in line with reports that document an 
ever-increasing dosage. Wood et al. reported that the MDMA content of 101 tablets obtained 
from amnesty bins cited in UK night clubs in 2006 was 58.7±22.9 mg per tablet, with a range 
of 20 mg to 131 mg per tablet [19]. 96% of tablets contained less than 100 mg MDMA per 
tablet. Subsequent reports have highlighted an increase in the content of MDMA in tablets. In 
2015, DIMS reported that 53% of tablets surveyed contained over 140 mg of MDMA. This 
contrasts with only 3% in 2009 and, furthermore, only 42% of tablets surveyed in this year 
contained more than 70 mg MDMA per tablet [46]. In 2018, DIMS reported that 72% of tablets 
surrendered contained >150 mg [41]. 95% of tablets contained more than 100 mg. The 
evaluation of 412 tablets collected over the period 2001-2018 in the UK provided evidence that 
recent samples (2018) contained a median content of MDMA of 105 mg for the first time [18].  
 
The MDMA-containing tablets tested in the present work confirm this continuing trend of 
tablets containing ever-greater amounts of MDMA. It should be noted that, although the 
amounts of MDMA found were not those of “super pills” (270-340 mg of MDMA per tablet) 
[22], each tablet contains 2.1-3.63 the amount needed to induce a physiological response in an 
average human [47] (62 kg). 
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